162 results on '"Avni-Biron, Irit"'
Search Results
2. Dysplasia detection rates under a surveillance program in a tertiary referral center for inflammatory bowel diseases: Real-world data
3. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα
4. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
5. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
6. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel
7. The Role of Small-Bowel Capsule Endoscopy in the Diagnostic Algorithm of Complicated Perianal Disease.
8. Machine learning for selecting patients with Crohn's disease for abdominopelvic computed tomography in the emergency department
9. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes
10. Discordant effects of ex-vivo JAK inhibition on inflammatory responses in colonic compared to ileal mucosa
11. Early Indolent Course of Crohn’s Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable
12. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study.
13. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD
14. A Real-World Prospective Cohort Study of Patients With Newly Diagnosed Crohn’s Disease Treated by a Multidisciplinary Team: 1-Year Outcomes
15. Dysplasia detection rates under a surveillance program in a tertiary referral center for inflammatory bowel diseases: Real-world data
16. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience
17. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases
18. Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data
19. Pregnancy Outcomes in a Cohort of Patients with Inflammatory Bowel Disease: Data from a Multidisciplinary Clinic in a Tertiary Center
20. DYSPLASIA DETECTION RATES IN A SURVEILLANCE PROGRAM REAL-WORLD DATA FROM A TERTIARY REFERRAL CENTER FOR INFLAMMATORY BOWEL DISEASES
21. The current place of probiotics and prebiotics in the treatment of pouchitis
22. Probiotics and prebiotics in Crohn's disease therapies
23. Peripartum Infections Among Women With Inflammatory Bowel Disease.
24. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study
25. Multidisciplinary Perinatal Care in IBD
26. Editorial: ustekinumab during pregnancy—reassuring but still not enough. Authors' reply
27. SARS-CoV-2 IgG Antibody Levels in Women with IBD Vaccinated during Pregnancy
28. Fecal Calprotectin and Quality of Life Questionnaires Are Responsive to Change in Pouch Disease Activity After Antibiotic Therapy: Results From a Prospective Clinical Trial
29. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study
30. Peripartum Infections Among Women With Inflammatory Bowel Disease
31. Immune function in newborns with in-utero exposure to anti-TNFα therapy
32. Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
33. Video-capsule endoscopy after bariatric surgery: a tertiary referral center experience
34. Sa1630: PATIENT AND PHYSICIAN PERSPECTIVE ON DISEASE CONTROL 1-YEAR AFTER DIAGNOSIS OF CROHN'S DISEASE: RESULTS FROM REAL-WORLD PROSPECTIVE INCEPTION COHORT
35. Su1564: USTEKINUMAB DURING PREGNANCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE MULTICENTER COHORT STUDY
36. Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES
37. Sa1601: FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT
38. Mo1557: DRUG PERSISTENCE AND ENDOSCOPIC, HISTOLOGIC AND BIOCHEMICAL REMISSION RATES AMONG PATIENTS FOLLOWING ILEAL-ANAL POUCH ANASTOMOSIS TREATED WITH BIOLOGIC THERAPY: RESULTS FROM A PROSPECTIVE PATIENT COHORT
39. 115 PHOTOPLETHYSMOGRAPHY WAVEFORM ANALYSIS DETECTS INFLAMMATORY STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
40. Sa1868 ALTERATIONS IN MICROBIAL COMPOSITION IN PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE OVER A COURSE OF ONE YEAR: DATA FROM A PROSPECTIVE LONGITUDINAL REAL-WORLD STUDY
41. 27 DEVELOPMENT AND VALIDATION OF AN INTEGRATED RISK SCORE FOR PREDICTING FUTURE RISK OF CROHN'S DISEASE UP TO 7 YEARS BEFORE DIAGNOSIS IN HEALTHY FIRST-DEGREE RELATIVES: THE CCCGEM PROJECT, A MULTICENTRE PROSPECTIVE COHORT STUDY
42. Su1813 EXTERNALLY VALIDATED ARTIFICIAL INTELLIGENCE EXPLAINABLE INTERACTIVE TOOL FOR PREDICTING AND COMPARING THE DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS
43. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience
44. Video Capsule Endoscopy after Bariatric Surgery: A Tertiary Referral Center Experience.
45. Fecal Calprotectin and Quality of Life Questionnaires Are Responsive to Change in Pouch Disease Activity After Antibiotic Therapy: Results From a Prospective Clinical Trial.
46. COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience
47. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
48. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
49. An Inception Cohort of Patients with Newly Diagnosed Crohn's Disease: Therapeutic Targets Achieved One Year after Diagnosis
50. Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.